Metahydroxylamine bitartrate injection

This product mainly acts on α receptors, directly stimulating α receptors. Its effect is weaker than that of norepinephrine but more persistent. Its cardiovascular effect is similar to that of norepinephrine. It can constrict blood vessels, continuously increase systolic and diastolic blood pressure, and enhance myocardial contractility. The cardiac output of normal people does not change much, but it can increase the cardiac output of patients with shock. The excitement of heart rate is not very significant, rarely causes arrhythmia, and has no central nervous system excitation effect. Because its pressor effect is reliable and lasts for a long time, it rarely causes reactions such as palpitations or decreased urine volume. When administered continuously, because this product indirectly replaces the transmitter in the adrenergic nerve vesicles, it can reduce the transmitter and weaken the intrinsic effect. Therefore, it cannot be stopped suddenly to avoid rebound hypotension.

（-）-α(1-aminoethyl)-3-hydroxybenzyl alcohol bitartrate

This product is a colorless clear liquid.

1. Prevent and treat acute hypotension during spinal block anesthesia; 2. This product can be used as an auxiliary symptomatic treatment for hypotension caused by bleeding, drug allergy, surgical complications, brain trauma or brain tumor combined with shock; 3. It can also be used for hypotension caused by cardiogenic shock or sepsis.

1 Adult dosage: (1) Intramuscular or subcutaneous injection: 2-10 mg/time (calculated as metaraminol). Since the maximum effect is not immediately apparent, the effect of the initial dose should be observed for at least 10 minutes before repeated use; (2) Intravenous injection, initial dose 0.5-5 mg, followed by intravenous drip, for severe shock; (3) Intravenous drip, add 15-100 mg of metaraminol to 500 ml of 5% glucose solution or sodium chloride injection and drip, adjust the drip rate to maintain appropriate blood pressure. The maximum dose for adults is 100 mg once (0.3-0.4 mg per minute). 2 Pediatric dosage: (1) Intramuscular or subcutaneous injection: 0.1 mg/kg, for severe shock; (2) Intravenous drip 0.4 mg/kg or 12 mg/m2 per body surface area, dilute with sodium chloride injection to a solution containing 1 mg of metaraminol per 25 ml, and drip at a rate to maintain an appropriate blood pressure level. The preparation should be used within 24 hours, and other drugs that are poorly soluble in acidic solutions and are incompatible with it should not be added to the infusion solution.

1 Arrhythmia. The incidence rate varies with dosage and patient sensitivity. 2 Too fast and too strong pressor reaction can cause acute pulmonary edema, arrhythmia, and cardiac arrest. 3 Overdose is manifested by convulsions, severe hypertension, and severe arrhythmia. At this time, the drug should be stopped immediately for observation. Those with high blood pressure can use 5-10mg phentolamine intravenous injection, which can be repeated if necessary. 4 Overflow of the drug during intravenous administration can cause severe contraction of local blood vessels, leading to tissue necrosis and erosion or redness, swelling, nodules, and abscesses. 5 Hypotension may occur if the drug is stopped suddenly after long-term use.

Not yet clear.

Precautions for children: Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly:

1. When used in combination with cyclopropane, halothane or other halogenated hydroxyl anesthetics, it is easy to cause arrhythmia. 2. When used in combination with monoamine oxidase inhibitors, the pressor effect is enhanced, causing severe hypertension. 3. When used in combination with digitalis or other adrenergic drugs, it can cause ectopic rhythm. 4. It is not suitable to be infused together with alkaline drugs, because it can cause the decomposition of this product.

Keep in a light-proof and airtight place.

Based on C9H13NO2 1ml:10mg

Southwest Pharmaceutical Co., Ltd.

• Founded in:

  2015-01-08

• Address:

  No. 21 Tianxing Bridge, Shapingba District, Chongqing

• Tax NO.:

  915000003316906249

• Registered Funds:

  490.146298 million yuan

• Website:

  Log in to view

• Email:

  Log in to view